全文获取类型
收费全文 | 722篇 |
免费 | 48篇 |
国内免费 | 45篇 |
专业分类
儿科学 | 49篇 |
妇产科学 | 3篇 |
基础医学 | 81篇 |
口腔科学 | 14篇 |
临床医学 | 95篇 |
内科学 | 178篇 |
皮肤病学 | 8篇 |
神经病学 | 52篇 |
特种医学 | 131篇 |
外科学 | 37篇 |
综合类 | 41篇 |
一般理论 | 1篇 |
预防医学 | 33篇 |
眼科学 | 7篇 |
药学 | 61篇 |
中国医学 | 3篇 |
肿瘤学 | 21篇 |
出版年
2022年 | 4篇 |
2020年 | 3篇 |
2018年 | 7篇 |
2015年 | 5篇 |
2014年 | 12篇 |
2013年 | 19篇 |
2012年 | 15篇 |
2011年 | 11篇 |
2010年 | 25篇 |
2009年 | 25篇 |
2008年 | 16篇 |
2007年 | 49篇 |
2006年 | 15篇 |
2005年 | 25篇 |
2004年 | 10篇 |
2003年 | 16篇 |
2002年 | 10篇 |
2001年 | 10篇 |
2000年 | 22篇 |
1999年 | 19篇 |
1998年 | 45篇 |
1997年 | 33篇 |
1996年 | 38篇 |
1995年 | 26篇 |
1994年 | 18篇 |
1993年 | 24篇 |
1992年 | 19篇 |
1991年 | 13篇 |
1990年 | 22篇 |
1989年 | 42篇 |
1988年 | 35篇 |
1987年 | 28篇 |
1986年 | 22篇 |
1985年 | 17篇 |
1984年 | 8篇 |
1983年 | 10篇 |
1982年 | 9篇 |
1981年 | 7篇 |
1980年 | 8篇 |
1978年 | 6篇 |
1977年 | 11篇 |
1976年 | 5篇 |
1975年 | 5篇 |
1973年 | 3篇 |
1969年 | 5篇 |
1967年 | 4篇 |
1966年 | 3篇 |
1965年 | 3篇 |
1963年 | 3篇 |
1941年 | 2篇 |
排序方式: 共有815条查询结果,搜索用时 15 毫秒
1.
2.
Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. 总被引:3,自引:0,他引:3
Robertson Parkman Geoff Cohen Shelly L Carter Kenneth I Weinberg Bernadette Masinsin Eva Guinan Joanne Kurtzberg John E Wagner Nancy A Kernan 《Biology of blood and marrow transplantation》2006,12(9):919-927
Allogeneic hematopoietic stem cell transplantation (HSCT) is established therapy for selected patients with acute leukemia. After transplantation, antileukemic immune responses are believed to eliminate residual leukemia cells and decrease the likelihood of relapse. However, the clinical effect of successful antigen-specific immune reconstitution after HSCT on the likelihood of leukemic relapse and overall survival is not known. Pediatric recipients of unrelated cord blood transplants who underwent transplantation for acute leukemia were sequentially evaluated for their development of antigen-specific T-lymphocyte immunity to herpes viruses. The clinical effect of a positive antigen-specific response on relapse-free survival was determined. The presence of an antigen-specific response resulted in a relapse-free survival advantage (P = .0001), which was primarily due to a decrease in leukemic relapse (P = .003). Proportional hazards modeling for time to relapse and time to relapse or death defined 3 variables that were strongly associated with a poor outcome: female gender, poor remission status before transplantation, and negative antigen-specific T-lymphocyte proliferation. Notably neither acute nor chronic graft-versus-host disease had any effect on the incidence of leukemic relapse. Successful antigen-specific immune reconstitution after unrelated cord blood transplantation results in decreased leukemic relapse and improved overall survival. 相似文献
3.
4.
Treatment of steroid-resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin 总被引:1,自引:0,他引:1
N A Kernan V Byers P J Scannon R P Mischak J Brochstein N Flomenberg B Dupont R J O'Reilly 《JAMA》1988,259(21):3154-3157
The A chain of the toxin ricin has been conjugated by a disulfide bond to a murine monoclonal antibody that recognizes the CD5 (T,p67) antigen present on 95% of peripheral blood T lymphocytes. This immunotoxin was used to treat a patient with severe grade III-IV, steroid-resistant, acute graft-vs-host disease (GvHD) after an allogeneic, human leukocyte antigen-identical bone marrow transplant for acute myelogenous leukemia. Immunotoxin therapy produced a complete clinical response in the skin and gastrointestinal tract. The patient tolerated a 14-day course without symptoms or signs of toxic effects. After two days of therapy, circulating T cells could not be demonstrated by indirect immunofluorescence. After therapy, acute GvHD did not recur. However, seven months after therapy the patient demonstrated mild signs of chronic GvHD that were easily controlled with low-dose immunosuppressive therapy. These findings indicate that an anti-T-cell ricin A chain immunotoxin can be given safely for treatment of acute GvHD and may be an effective therapy for this significant posttransplant complication. 相似文献
5.
6.
7.
8.
Sperm quality in Hodgkin's disease versus non-Hodgkin's lymphoma 总被引:3,自引:4,他引:3
Botchan A; Hauser R; Gamzu R; Yogev L; Lessing JB; Paz G; Yavetz H 《Human reproduction (Oxford, England)》1997,12(1):73-76
The study was conducted to determine the deleterious effect of lymphoma
disease on spermatogenesis and to evaluate the possibility that the disease
is mediated primarily by inherent mechanisms in Hodgkin's disease and
non-Hodgkin's lymphoma patients. A total of 89 patients with lymphoma
disease (Hodgkin's and non-Hodgkin's) were referred for sperm preservation
prior to adjuvant treatments. A comparison was made of pre- and post-thaw
sperm quality between lymphoma patients and healthy volunteers who applied
for sperm donation. This was followed by further assessment of the
differences between patients with Hodgkin's disease and non-Hodgkin's
lymphoma in terms of sperm variables, clinical parameters and blood hormone
concentrations. It was found that patients with lymphoma disease had
significantly impaired pre-freeze and post-thaw sperm quality compared with
that of healthy volunteers. Patients with non-Hodgkin's lymphoma had
spermatozoa of higher quality than patients with Hodgkin's disease. No
differences were found in the clinical or hormonal parameters between these
two groups. As expected, reduced testicular size and abnormal testicular
consistency were correlated with decreased sperm quality. The mere presence
of cancer disease has a direct negative effect on spermatogenesis, which is
probably not related to incidental side-effects. A variable degree of
impairment should be expected with different categories of cancer.
相似文献
9.
Joseph H Chewning Hugo Castro-Malaspina Ann Jakubowski Nancy A Kernan Esperanza B Papadopoulos Trudy N Small Glenn Heller Katharine C Hsu Miguel A Perales Marcel R M van den Brink James W Young Susan E Prockop Nancy H Collins Richard J O'Reilly Farid Boulad 《Biology of blood and marrow transplantation》2007,13(11):1313-1323
Graft failure is associated with a high mortality rate. To date, regimens invoked for second transplants have resulted in inconsistent engraftment with high transplant-related mortality (TRM). We here report 16 consecutive patients, aged 4-59 years, who received second HSCT (HSCT-2) at a median of 45 days following primary or secondary failure of an initial unmodified (N = 3) or T cell-depleted (TCD) (N = 13) HSCT (HSCT-1). HSCT-1 was administered after myeloablative total body irradiation (TBI)- or alkylator-based conditioning for acute leukemias (N = 7), MDS (N = 6), CML (N = 2), and Fanconi anemia (N = 1). All patients experienced 1 or more infectious complications between HSCT-1 and HSCT-2, and 10 patients had active infections at the time of HSCT-2. Cytoreduction regimens used for HSCT-2 included fludarabine (Flu) in combination with cyclophosphamide (CTX) (N = 9), or thiotepa (Thio) (N = 5). In addition, 1 patient received Flu alone and 1 patient Thio combined with CTX. Antithymocyte globulin (ATG) (N = 11) or Alemtuzumab (N = 3) was added pretransplant to prevent rejection. For HSCT-2, donors included HLA-matched (N = 3) or mismatched (N = 8) related, or matched (N = 2) or mismatched (N = 3) unrelated donors. The primary graft donor was used in 6 of 16 cases. The grafts administered were unmodified peripheral blood stem cell transplantation (PBSCT) (N = 5) or bone marrow transplantation (BMT) (N = 3), TCD PBSCT (N = 8). All patients achieved engraftment at a median of 12 days and evaluable patients achieved complete donor chimerism. Six patients are alive with a median follow-up of 49 months, including 4/9 conditioned with Flu/CTX. In this series, outcome was statistically superior for younger patients (相似文献
10.
Kernan WN Viscoli CM Brass LM Makuch RW Sarrel PM Horwitz RI 《Stroke; a journal of cerebral circulation》2000,31(2):415-419
BACKGROUND AND PURPOSE: After a transient ischemic attack or stroke, the risk for recurrence may be reduced by treatment of hypertension. The purpose of this study was to determine how commonly blood pressure exceeds national guidelines among patients who have had one of these events. METHODS: Subjects were 644 women participating in a randomized trial of estrogen for secondary stroke prevention. We measured blood pressure 1 month after the stroke or TIA while patients were under the care of their personal physicians. Among 536 patients, a second measure was made at an average of 2.9 years after the first. RESULTS: The mean age of participants was 71 years, and 73% reported a history of hypertension. At baseline, only 44% (280/644) of the women had blood pressure values within national guidelines (<140/90 mm Hg). With separate guidelines used for diabetics (<130/85 mm Hg) and nondiabetics (<140/90 mm Hg), the proportions of women within the guidelines were 27% and 44%, respectively. Overall, 39% of patients were within the diabetes-adjusted guidelines. Among patients whose blood pressure exceeded 140/90 mm Hg at first examination, 55% were still in excess at follow-up. Features associated with severe hypertension at first examination (>160/100 mm Hg) were history of hypertension, education less than college, and higher cognitive functioning. CONCLUSIONS: Blood pressure values in excess of national guidelines are common after stroke and TIA, especially among diabetic patients. Efforts to lower blood pressure control may enhance secondary prevention. 相似文献